Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Common Equity (2016 - 2025)

Historic Common Equity for Evogene (EVGN) over the last 15 years, with Q2 2025 value amounting to $12.4 million.

  • Evogene's Common Equity fell 3793.88% to $12.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $12.4 million, marking a year-over-year decrease of 3793.88%. This contributed to the annual value of $14.8 million for FY2024, which is 2310.63% up from last year.
  • Evogene's Common Equity amounted to $12.4 million in Q2 2025, which was down 3793.88% from $14.8 million recorded in Q4 2024.
  • Over the past 5 years, Evogene's Common Equity peaked at $82.1 million during Q1 2021, and registered a low of $12.1 million during Q4 2023.
  • Over the past 5 years, Evogene's median Common Equity value was $31.1 million (recorded in 2023), while the average stood at $37.8 million.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 39509.09% in 2021, then crashed by 6587.57% in 2024.
  • Quarter analysis of 5 years shows Evogene's Common Equity stood at $53.7 million in 2021, then tumbled by 47.94% to $27.9 million in 2022, then plummeted by 56.85% to $12.1 million in 2023, then increased by 23.11% to $14.8 million in 2024, then decreased by 16.6% to $12.4 million in 2025.
  • Its last three reported values are $12.4 million in Q2 2025, $14.8 million for Q4 2024, and $12.2 million during Q3 2024.